A Study of Bevacizumab Combined With Fluzoparib/Chemotherapy or Fluzoparib in the Treatment of Ovarian Cancer

Sponsor
The Second Affiliated Hospital of Shandong First Medical University
Study ID
NCT05170594
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Bevacizumab — DRUG
    Bevacizumab will be administered at 15mg/kg IV, every 3 weeks
  • chemotherapy — DRUG
    The non-platinum chemotherapy regimen will be determined by the investigator.
  • Fluzoparib — DRUG
    Fluzoparib will be administered orally continuously at 150mg bid until disease progression and toxicity becomes intolerable

Study Details

This study was designed to explore the safety and efficacy of Bevacizumab combined with Fluzoparib, Bevacizumab combined with chemotherapy or Fluzoparib monotherapy in patients with platinum-resistant recurrent ovarian cancer.

Key Dates

First listed
Dec 28, 2021
Start date
Dec 24, 2021
Status verified
Dec 2021
Primary completion
Jun 30, 2024
Completion
Jun 30, 2024

Study Design

Enrollment
60 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Bevacizumab combined with Fluzoparib
    Bevacizumab combined with Fluzoparib will be administered in patients with platinum-resistant recurrent ovarian cancer.
  • Experimental: Bevacizumab combined with chemotherapy
    Bevacizumab combined with non-platinum chemotherapy will be administered in patients with platinum-resistant recurrent ovarian cancer.
  • Experimental: Fluzoparib
    Fluzoparib monotherapy will be administered in patients with platinum-resistant recurrent ovarian cancer.

Primary Outcome Measure

Progression-Free-Survival [ Time Frame: 2 years ]

Central Contacts

Related Studies